multiple myeloma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged at least 18 years. 2. Newly diagnosed as having MM according to the updated IMWG diagnostic criteria 2014 requiring treatment. 3. Not eligible for stem cell transplantation. 4. EGCO 0-3. 5. Estimated survival times over 6 months. 6. No receive any anti-tumor therapy (single use of glucocorticoid excluded). 7. Meet all of the following blood criteria within 14 days before therapy: a. Total bilirubin <= 3 x upper limit of normal (ULN). b. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <= 3 x ULN. 8. Meet the pregnancy prevention requirements: not of childbearing potential or agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug. 9. Able to provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Received other clinical trials for multiple myeloma within three months. 2. Received previous treatment for MM (single use of glucocorticoid excluded). 3. Prior or concurrent invasive malignancies. 4. Active systemic infection or any other medical or psychiatric condition which, in the opinion of the investigator, contraindicates the participant's participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate;toxicity; | — |
Countries
China
Contacts
The First Affiliated Hospital, Sun Yat-Sen University